ArcticZymes Technologies (AZT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was NOK 24.1 million, down from NOK 31.2 million in Q3 2023, with EBITDA at NOK -2.3 million compared to NOK 7.3 million last year, mainly due to weak Molecular Tools sales and inventory adjustments by key accounts.

• Biomanufacturing sales reached NOK 12.7 million, showing sequential growth for the third consecutive quarter and now accounting for 56% of Q3 sales.

• The company is accelerating its commercial transformation, including the appointment of a new VP of Sales and increased investment in headcount, marketing, and customer-centric initiatives.

• Strategic focus includes expanding OEM and CDMO partnerships, launching new GMP-grade nucleases and an ELISA kit, and broadening the product portfolio into advanced therapies and mRNA therapeutics.

• Notable innovation includes the publication of a peer-reviewed article on a novel RNA restriction enzyme, generating significant industry interest.

Financial highlights

• Q3 2024 sales revenue was NOK 24.1 million (down from NOK 31.2 million in Q3 2023); year-to-date revenue was NOK 79.8 million, an 11–12% decline year-over-year.

• Q3 EBITDA was NOK -2.3 million (adjusted: NOK -1.0 million after ERP costs); net profit for Q3 was NOK -1.6 million.

• Gross profit margin for Q3 2024 was 93%, with gross margins above 90% across all products.

• Operating expenses increased, mainly due to ERP implementation and reduced capitalization of projects.

• Cash and short-term investments at quarter-end were NOK 170–240 million, with no interest-bearing debt.

Outlook and guidance

• SAN OEM agreement negotiations are ongoing, with revenue contribution expected in Q2/Q3 2025, contingent on successful completion.

• CDMO platform integration and adoption of SAN products are progressing, with implementation targeted for 2025.

• Two new GMP-grade nucleases and a more sensitive ELISA kit will be launched within the next 8 months.

• Continued investment in commercial transformation and marketing, with further headcount and resource allocation planned, expected to impact short-term profitability but drive long-term growth.

• The Molecular Tools segment is expected to improve in Q4 and grow in 2025, though still dependent on key account order timing.